J.P.
Yield10 Bioscience Inc (NASDAQ:YTEN) shares are shooting up 268% faster than Jack’s magic bean sparking right into a giant beanstalk, thanks to today’s …
Monday turned out to be a nightmare for PhaseRx Inc (NASDAQ:PZRX) investors after the biopharmaceutical firm announced that it has filed for Chapter …
This billion-dollar hedge fund initiates new position in struggling pharma TEVA as exits VRX.
Roth Capital’s Yasmeen Rahimi still pinpoints almost 30% upside potential for GALT shares following the biotech firm’s failed Phase 2b trial.
H.C.
Canaccord’s John Newman now sees almost 18% in upside potential for SAGE following a big clinical home run in major depressive disorder.
Experienced investors in search of growth know to look beyond current trends and market momentum or rely on pundit’s expectations. Today’s results are …
Canaccord’s Richard Davis anticipates VEEV stock can move up consistently sometime by the first half of next year.
